Evaluation of Target Organs Damage in Hypertensive Patients

2014-08-27 03:16:26 | BioPortfolio


Evaluation of target organs damage in hypertensive patients with no known cardiovascular (CV) or renal disease, stratified according to level of blood pressure control

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional


Target Organs Damage


Research Site





Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:16:26-0400

Clinical Trials [439 Associated Clinical Trials listed on BioPortfolio]


Study outline: Deferasirox (Exjade®) is regularly used in severe iron overload in order to avoid organ damage of liver, heart and other organs. It has been proposed, that iron overload ma...

Antihypertensive Treatment in Masked Hypertension for Target Organ Protection

The primary purpose of the study is to estimate the target organ protection after 12 months of antihypertensive treatment in masked hypertension patients with at least one kind of target o...

Relationship of Central Blood Pressure and Pulse Wave Velocity With Target Organ Damage

Diabetic patients show an increased prevalence of non dipping arterial pressure pattern, target organ damage and elevated arterial stiffness. These alterations are associated with increase...

Damage Control Laparotomy

Randomized study to compare outcomes of patients undergoing damage control laparotomies versus definitive closure for which there is surgeon equipoise to randomize.

The Potential Role of Testosterone on Target Organ Damage in Postmenopausal Hypertensive Women

The incidence of CVD-related deaths is generally higher in women than men. Postmenopausal changes in estrogen/androgen ratio that induce a relative androgen excess have been proposed as im...

PubMed Articles [9949 Associated PubMed Articles listed on BioPortfolio]

ESC Council on hypertension position document on the management of hypertensive emergencies.

Hypertensive emergencies are those situations where very high blood pressure (BP) values are associated with acute organ damage, and therefore, require immediate, but careful, BP reduction. The type o...

Quantitation of DNA Adducts in Target and Non-Target Organs of Aristolochic Acid I-Exposed Rats by LC-MS/MS Coupled with Stable Isotope-Dilution Method: Correlating DNA Adduct Levels with Organotropic Activities.

Chronic exposure to aristolochic acids (AAs) from Aristolochia plants is one of the major causes of nephropathy and cancer of the kidney and forestomach. However, the organotropic activities of AAs re...

Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs.

The platinum-based drug cisplatin is a widely used first-line therapy for several cancers. Cisplatin interacts with DNA mainly in the form of Pt-d(GpG) di-adduct, which stalls cell proliferation and a...

Target Therapy in SLE.

The intention of this paper is to review actual developments in target therapy in SLE. Target therapy includes both the objective of intervention and the aim of treatment. The objective should be link...

Aortic stiffness, pressure and flow pulsatility and target organ damage.

Measures of aortic stiffness and pressure and flow pulsatility have emerged as correlates of and potential contributors to cardiovascular disease, dementia and kidney disease. Higher aortic stiffness ...

Medical and Biotech [MESH] Definitions

The use of pre-treatment imaging modalities to position the patient, delineate the target, and align the beam of radiation to achieve optimal accuracy and reduce radiation damage to surrounding non-target tissues.

Specialized organs adapted for the reception of stimuli by the NERVOUS SYSTEM.

Organs which might be damaged during exposure to a toxin or to some form of therapy. It most frequently refers to healthy organs located in the radiation field during radiation therapy.

A field of medicine concerned with developing and using strategies aimed at repair or replacement of damaged, diseased, or metabolically deficient organs, tissues, and cells via TISSUE ENGINEERING; CELL TRANSPLANTATION; and ARTIFICIAL ORGANS and BIOARTIFICIAL ORGANS and tissues.

A cyclin G subtype that is constitutively expressed throughout the cell cycle. Cyclin G1 is considered a major transcriptional target of TUMOR SUPPRESSOR PROTEIN P53 and is highly induced in response to DNA damage.

More From BioPortfolio on "Evaluation of Target Organs Damage in Hypertensive Patients"

Quick Search


Relevant Topics

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Searches Linking to this Trial